JP Morgan Lowers Price Target for Universal Health Services (UHS) to $195

JP Morgan has lowered the price target for Universal Health Services (UHS) to $195, a 9.30% decrease, while maintaining a "Neutral" rating. The updated price target reflects changes in sentiment and projections among analyst ratings. The company's revenue is primarily generated from its acute care hospitals, and the average target price for UHS is $221.13, indicating a 33.26% upside from the current price of $165.94.

Title: Analysts' Target Prices and CoreCard's Future Uncertainty

Analysts have adjusted their price targets for several key stocks, reflecting shifts in market sentiment and projections. The iShares S&P 500 Value ETF (IVE), which tracks the S&P 500 Value Index, has seen analysts set a target price of $221.85 per unit, indicating a 12.84% upside from its recent price of $196.60 [1]. Among its holdings, Accenture plc (ACN), Cooper Companies, Inc. (COO), and Universal Health Services, Inc. (UHS) stand out with notable upside potential.

Accenture plc (ACN) has an analyst target price of $339.61 per share, representing a 37.19% increase from its recent price of $247.54. Similarly, Cooper Companies, Inc. (COO) has a target price of $92.93 per share, which is 36.43% above its recent price of $68.12. Universal Health Services, Inc. (UHS) has a target price of $221.44 per share, a 35.45% increase from its recent price of $163.48 [1].

Meanwhile, JP Morgan has lowered its price target for Universal Health Services (UHS) to $195, a 9.30% decrease from its previous target, while maintaining a "Neutral" rating. This adjustment reflects changes in analyst sentiment and projections. UHS's revenue primarily comes from its acute care hospitals, and the average analyst target price of $221.13 indicates a 33.26% upside from its current price of $165.94 [2].

Separately, Apple's potential shift to JP Morgan for its credit card business could put Georgia-based CoreCard (NYSE:CCRD) at significant risk. CoreCard's credit card business is a major part of its revenue, and losing Apple as a client could have a substantial impact on its financials. The shift to JP Morgan could be a result of Apple ending its partnership with Goldman Sachs [2].

The challenges remain for CoreCard, including the absence of late payment penalties, which limits profitability and increases risk. CoreCard is not used by any other major bank, and the payment-processing industry is dominated by a handful of giants [2].

References:
[1] https://www.nasdaq.com/articles/how-pieces-add-ive-headed-222
[2] https://www.ainvest.com/news/corecard-partnership-apple-risk-apple-reportedly-considers-shifting-jp-morgan-2508/